Date: 2016-12-20
Type of information: Series A financing round
Company: Phi Pharma (Switzerland)
Investors: undisclosed investor
Amount: CHF 3.7 million
Funding type: series A financing round
Planned used:
- Phi Pharma is a private Swiss-based biopharmaceutical company. It specializes in the discovery and early development of peptide drug conjugates for improving the treatment of diseases with high unmet medical needs. The Phi Pharma technology is based on a powerful new class of
peptide drug conjugates with specific cellular targeting and efficient intra-cellular delivery. The lead programs are in oncology, infectious diseases and autoimmune diseases.
- The company has assembled a group of successful entrepreneurs and investors from the biotech industry, including early backers of Swiss biotech companies such as Actelion, Axovan, Molecular Partners, Kuros and Novimmune.
The financing will allow Phi Pharma to demonstrate ex-vivo efficacy in patient derived tumour cells and select the optimal clinical candidate to take forward into clinical trials in the first oncology indication.
CEO Tom Shepherd recently joined the company, bringing decades of experience in building development stage biotech start-ups in the UK, France and the USA.
Others:
- • On December 20, 2016, Phi Pharma announced the closing of a CHF 3.7m Series A financing, led by an undisclosed investor.
Therapeutic area: Cancer - Oncology - Infectious diseases
Is general: Yes
